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Clonal predominance of cytomegalovirus-specific CD8+ cytotoxic T 
lymphocytes in bone marrow recipients
H Dolstra, E Van de Wiel-van Kemenade, T De Witte and F Preijers
Summary: still unclear. GVHD and virus infections may be involved
in an antigen-driven expansion of CD8f T cells. The pres- 
After lymphocyte-depleted BMT, C D 81 T cells have ence of several predominant TCR transcripts after BMT 
been expanded to or above normal levels in 45 % of the supports this hypothesis, 4 However, so far no specific 
recipients within 3 months. The mechanisms underlying antigens :ing expansion r  cells and TCR
proliferation of donor-derived CDS' T cells after BMT donality after BMT have been identified.
Expansion of CDS ' T cells after BMT was accompanied
ar toby CD57 expression.2 CD8*CD57+ T
mediate non-MHC-restricted cytotoxicity after activation
are still unclear. We investigated whether these CI)8+
T cells proliferate in response to specific antigens by 
determination of TCR donality and whether these cells 
exert specific cytotoxicity. PCR analysis of TCR-y gene with 1L-2 or CD3 antibodies.7 l’ In addition, cytotoxicity of 
rearrangements showed a marked clonal predominance allospecific CTL or natural killer cells as well as mitogen- 
in CD8+ T cells of recipients with a high number of these induced B and T cell proliferation can be inhibited by
CD8+CD57+ T cells.10-11 However, in vitro s ationcells. Strong association between expansion of CD8+ T 
cells and CMV infection suggests involvement of CMV CD8+CD57~ T cells in secondary mixed lymphocyte reac- 
antigens. Therefore, we examined CMV-specific cyto- tion or with IL-2 induces expression of CD57.12 Therefore,
toxicity of freshly isolated CD8+ T cells of two BMT 
recipients with clonal expansion after the onset of CMV
it is not clear whether CD8+CD57+ T cells are a distinct 
lymphocyte subpopulation with unique functional proper-
infection. CD8+ T cells exerted HLA-restricted cytotox- ties or are derived from CD8fCD57 T cells by differen 
icity directed against CMV-infected fibroblasts indicat­
ing that CMV stimulates proliferation. The majority of 
€1)8' T cells in these recipients expressed CD57. We 
demonstrated that TCR donality was irrespective of 
CI)57 expression. Both CD8 CD57' and CD8 CD57" T 
cells showed significant HLA-restricted CMV-specific
nation or activation.
The increase of CD8' T cells in BMT recipients seems 
to be the result of stimulation by viral antigens and minor
ZJ 1,13 15 We, and others, have
cytotoxicity. These studies str suggest that CMV
antigens can induce expansion of clonal CDS' T cells 
after BMT.
Keywords: BMT; CD8' T cell expansion; CMV, TCR 
donality; cytotoxicity
that CD81 T cell expansion after BMT is signifi­
cantly correlated with CMV infection but independent of
2,10.1.1 This suggests that CMV antigens are involved)C
in proliferation of these CD8+ T cells. Therefore, we stud- 
CMV-speeilic cytotoxicity and clonal expansion 
1 T cells in BMT recipients. Our data strongly suggest 
that proliferation of CD8' T cells by CMV antigens after 
BMT results in a clonal expansion of donor-derived CD8+ 
T cells, of which the majority express CD57.
Allogeneic BMT is an effective treatment for patients with
restoration of both hematopoiesis and 
is essential for the long-term success of
this treatment. Donor-derived T cells have 
recipient to restore 1 
variable in the peripheral
s and functions 
of time.1
Previously, we found that CD81 T cells were 
or above normal levels in 45% of recipients of
ate the 
M's are
WiI
a pro-
T 3
nals responsible for proliferation of these CD8* T cells are
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Materials and methods
Patient description and cell isolation
For this study eight BMT recipients with an expansion of 
CD81 T cells and three control BMT recipients with low
of CD8 ' T P* *
received allogeneic bone marrow, lymphocyte-depleted by 
counterflow centrifugation, from an HLA-identical, MIX’
-to* All patients orally acyclovir
(4 x 400 mg/day) from days -9  to 60 as prophylaxis of 
herpes virus infection. CMV infection 
ganciclovir or hyperimmune globulin was not 
GVHD status, CMV status and T cell phenotype data of 
the BMT recipients studied are given in Table l. Peripheral
and marrow wei from
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Table I Patient characteristics
UPN GVHD"
Acute Chronic
CMV statusb 
Serology D/R jinfection1
CD4 ' PBL
( x i o v i r
M  II ■ 1  » I I  1 1 » 1 1 —1 II
CD8* PBL
(x io 'v ir
CD8'CD57' 
PBL ( % )
BMT recipients with high numbers of CDS ’ T cells
177 1 L ~h/'h 0.19 0.62 60
189 I 0 +/+ — 0.45 2.71 71
191 II L +/+ — 0.66 3.38 65
220 0 E +/+ + 0.17 1.02 65
227 I L -/+ 1.10 2.55 53
247 I L +/+ 0.12 1.19 62
257 II E +/+ + 0.20 0.67 49
265 I L +/+ w|w 0.73 3.07 51
BMT recipients with low numbers of CD8+ T cells 
232 1 L 0.10 0.34 14
233 I L »nij 0.12 0.12 9
236 I 0 -/+ — 0.23 0.14 11
UPN = unique patient number; D = clonor; R = recipient; PBL = peripheral blood lymphocytes.
“Acute and chronic GVHD: acute GVHD, stages 0 to IV; chronic GVHD, no (0), limited (L) or extensive (E).
hCMV status: CMV serology prior to BMT of clonor and recipient; CMV infection defined by the presence of CMV antigen in blood and/or CMV in 
cultures of urine samples.
cAbsolute number of CD4+ and CD8+ PBL at time TCR clonality analysis was performed between 3 and 12 months after BMT. Normal range of analysis 
of peripheral blood of 20 normal individuals: CD4+ 0.57-0.97 x 10‘Yl and CD8+ 0.28-0.56 x 10'Vl.
donors and peripheral blood samples from BMT recipients 
between 3 and 12 months after BMT. PBMC and BMMC 
were isolated by using Ficoll-Paque (Pharmacia, Uppsala, 
Sweden) and washed twice in PBS before use. PBMC of 
all patients studied were of donor origin.
CMV monitoring
IgG, IgA and IgM antibodies to CMV were tested prior to 
BMT in the serum of both donor and recipient using an 
ELISA. An antibody titer of >  10 was considered positive. 
The presence of CMV in urine samples was determined 
using a standard method. Briefly, the fibroblast cell line 
HEL was grown to confluence in flat-bottom tubes contain­
ing a coverslip. Tubes with cells were inoculated with urine 
specimens by centrifugation for 45 min at 37°C. After 48 
h cells were fixed with methanol for 20 min at 4°C and
(CD57; Becton Dickinson, Mountain View, CA, USA). 
Cells were incubated with the appropriate concentration of 
moAb in PBS supplemented with 20% pooled human 
serum and 0.1% NaN3 (4°C, 30 min). Cells were washed 
in PBS supplemented with 1% BSA and analyzed on an 
Epics XL flow cytometer (Coulter Electronics, Hialeah,
FL, USA).
Isolation of lymphocyte subpopulations
CD4+ and CD8+ T cells were obtained by positive selection 
using immunomagnetic beads. Briefly, PBMC were washed 
twice and resuspended in PBS with 2% FBS (Integro, Zaan­
dam, The Netherlands) at a concentration of 10 to 20 x 10h 
cells/ml. Cells were incubated (4°C, 45 min) with either 
anti-CD4 or anti-CD8 immunomagnetic beads (Dynal, 
Oslo, Norway) on a rotating shaker. Cells bound to beads
examined for detection of immediate-early antigen with the were isolated using a magnet. Beads were detached by 
MoAb NEA-9221 (Dupont, Dreieich, Germany) by indirect Detachabead antibody solution (Dynal) on a rotating shaker 
immunofluorescence. The presence of the CMV antigen in (RT, 1 h). Cells were collected, washed and tested 
blood was determined using a standard method. Briefly, 
granulocytes were isolated from citrate-anticoagulated 
blood by dextran. Cytospin preparations (1.5 x 105 
cells/cytospin) were fixed with acetone for 10 min at room 
temperature (RT) and examined for detection of pp65 anti­
gen with the MoAbs CMV-C10 and CMV-C11 (Biotest,
Dreieich, Germany) by indirect immuno-alkaline phophat- (4°C, 30 min). Cells were washed once with PBS and 
ase staining. CMV infection was defined by the presence sorted cells were collected in IMDM (Gibco, Paisley, UK) 
of CMV antigen in blood and/or CMV in cultures of containing 10% FBS. An aliquot of sorted cells was
purity by immunofluorescence analysis. Purity was more 
than 98%.
CD3+, CD8+CD57+ and CD8+CD57 T cells were iso­
lated by cell sorting with an Epics Elite flow cytometer 
(Coulter). Briefly, PBMC or isolated CD8+ T cells were 
incubated with the appropriate concentration of moAb
urine samples. reanalyzed and purity was more than 95%.
Antibodies and immunofluorescence EBV transformation and CMV infection
The following moAb were used for phenotypic analysis: EBV-lymphoblastoid cell lines (EBV-LCL) were genen
FITC- or PE-conjugated UCHT1 (CD3), MT310 (CD4), from PBMC by transformation with EBV of the EBV-s
DK25 (CDS; Glostrup, Denmark) and Leu7 ding B95-8 cell line and 0.1 /¿g/ml cyclosporin A.
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was determined by single-stranded conformational poly­
morphisms (SSCP). The SSCP technique is based on the
EBV-LCL were cultured in IMDM containing 10% FBS.
Fibroblasts were isolated from bone marrow obtained from 
marrow donors as follows. BMMC were suspended at 
2 x lOVml in IMDM with 20% FBS and were maintained in 
IMDM containing 10% FBS. Fibroblasts between passages 
three and 10 were used for CMV infection. CMV strain 
AD 169 was grown in fibroblast cell line HEL infected at 
a multiplicity of infection (MOI) of 5. Infectious super- heated at 85°C for 3 min and cooled on ice for 10 min. A 
natant was harvested when 100% of the fibroblasts showed 3 /xl sample was loaded onto a SSCP gel (5% polyacryl-
mation and electrophoretic mobility of
DNA in a non-denaturating polyacrylamide 
The PCR products were diluted 1:4 with SSCP 
loading buffer (96% formamide, 20 mM EDTA, 20 him
NaOH, 0.05%
gel. 18, IV)
a cytopathic effect in order to prepare an AD 169 stock with amide; acrylamide:N,N'bis acrylamide = 49: i, 0.5 x TBE
a titer of 3 x 106/ml. AD 169 stocks were stored at -70°C. buffer, with or without 5% v/v glycerol). Single strand pro-
Fibroblasts were infected with CMV strain AD 169 at a ducts were electrophoresed at 2 W for 6000 Volt hour in 
MOI of 5 in 5 ml IMDM containing 10% FBS for 18 h. 0.5 x TBE buffer. Gels were autoradiographed by exposing
to ; XAR films.
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Cvtotoxi ci tv assay
Cytotoxicity of isolated lymphocyte subpopulations 
assayed by 5lCr-release of labeled target cells. EBV-LCL 
were labeled with 100 /xCi 5lCr (Amersham, Bucks, UK) 
for 1.5-2 h. Fibroblast targets were preincubated before
with 100 U/ml IFN-y (Boehringer
Results
TCR clonality in BMT recipients
Previously, we found that in 45% of recipients of lympho
Zaandam, The Netherlands) for 2 to increase bone marrow allografts CD8 * T
expression of MHC molecules which leads to an increased expanded to or above normal levels within 3 months after 
susceptibility of the fibroblasts for TCR-mediated cytotox- BMT. In these recipients the mean number of CD8+ T cells
icity. Fibroblasts were infected and labeled simultaneously 
with 150 fiCi 5lCr for 18 h. Labeled target cells were mixed
at 3 months after BMT was significantly higher than
in normal individuals (1.06 ± 0.92 x 10tJ/l
in V-bottom microtiter plates (103/well) with various num- 0.42 ±  0 .14x  109/1, respectively; P <  0 .001).2 The inci-
bers of effector cells in 150 p i  IMDM with 10% FBS. 
Plates were centrifuged (50 g, 5 min) and incubated at 37°C
dence of CMV infection after BMT was significantly higher 
in recipients with high numbers of CD8+ T cells (12/17)
for 4 h. After incubation 100 ¡x\ supernatant of each sample than in recipients with low numbers (2/21, P <  0.001 ).2
was collected and radioactivity was by a The median time of onset of CMV infection was 9 weeks
gamma counter. Spontaneous 5lCr release was determined (range 5 
by incubating target cells in medium alone and maximum 
MCr release by target cells incubated in 10% Triton X-100.
s is e
(experimental release
calculated as: lOOx 
release )/( maximum
Spontaneous in
T cells in these
the result of a fast polyclonal repopulation or clonal pro-
TCR clonality of purified T 
Eight BMT recipients with high num- 
T cells were compared with three BMT
and T cell 
bers of
the absence of CTL was <25%  of maximum release by recipients with low numbers of CD81 T cells (Table 1). Six
detergent in all experiments.
TCR - y  PCR analysis
out of the eight recipients with high numbers of CD8+ T 
cells had an active CMV infection after BMT (Table 1).
Rearranged TCR Vy-Jy segments analyzed by the sensi­
tive PCR-SSCP technique allows detection of in vivo clonal
TCR clonality of isolated lymphocyte subpopulations was T cell expansions. Analysis of T cells isolated from BMT
recipients with an expansion of CD8+ T cells showed pre­
dominant bands and relatively low polyclonal background 
in the TCR-y products (Figure la). BMT recipients with 
low numbers of C
by TCR-y PCR analysis, 
washed twice in PBS and 0.6 x  IQ6 cells were resus 
in 100 ix 1 1 x  PCR buffer (50 ihm KC1, 20 him Tris (pH
8.4), 1.5 mM 0.01% BSA)
0.45% v/v Nonidet P40 and 0.45% v/v Tween
was incubated with proteinase K (0.1
T cells showed less pre
; l l  ly s i
at 55°C for
bands and more prominent polyclonal background in the 
TCR-y products (Figure lb). TCR-y products of T cells of
1 h. Finally, cell lysate was heated at 95°C for 10 min to normal individuals are visualized by this PCR-SSCP aiutly- 
denaturate proteinase K and cell lysate was stored at -80°C. sis as a smear in contrast to clonal TCR-y products of the 
The oligonucleotides C20/10 and T20/10 were used to T cell line Jurkat (Figure Ic). These data demonstrate that
2 of ream *1 t* L
prime the amplification of an approximately 400-bp region a number of distinct predominant T cell clones were present 
of rearranged TCR-y locus involving V yl subgroup genes in BMT recipients with an expansion of CD8+ T cells. Pre- 
and Jyl/Jy2 genes.17 Rearranged TCR-y DNA of 10 pA cell 
lysate was amplified by PCR ip 100 /¿l I x PCR buffer 
supplemented with 100 pmol each primer, 0,06 h i m  dNTPs,
2.5 U Taq polymerase (Life Technologies) and -^P-adCTP 
(Amersham), for 30 cycles (94°C for 1 min, 55°C for 2
Vy-Jy se 
in CD4+ T cells of all recipients predominant
al T ceils (data not s
I T
;r, less po ly-
al CD8' T cells of BMT
min, and 72°C for 3 min). Finally, samples were incubated recipients before and after the onset of CMV infection.
at 72°C for 10 min and cooled to 4°C. TCR-y clonality CD8+ T cells increased i onset of CMV infection
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Figure 1 PCR-SSCP analysis of TCR-y gene rearrangement in BMT recipients and normal individuals of sorted CD3* T cells, (a) Five recipients with 
expansion of CD8+ T cells after BMT. (b) Three recipients with low numbers of CD8+ T cells after BMT. (c) Controls, normal individuals with a 
polyclonal pattern and T cell line Jurkat with a clonal pattern.
(Figure 2a). Simultaneously, predominant bands were Role o f CD57 expression on CD8+ T cells in TCR 
detected in the TCR-y PCR product of these CD8+ T cells
(Figure 2b). High numbers of CD8+ T cells and TCR clon­
ality persisted at least 1 year after BMT.
TCR clonality of CD8+ T cells in BMT recipients with 
high numbers of these cells suggests an antigen-induced 
proliferation.
CMV-specific cytotoxicity mediated by purified CDS' T 
cells
T cells specifically recognize and proliferate on CMV 
antigens.
clonality and CMV-specific cytotoxicity
The majority of CD8+ T cells in recipients with high num­
bers of these cells express CD57 while only a low percent­
age of the CD8+ T cells in recipients with low numbers
coexpress CD57 (Table 1). It has
of CD57 is strongly cor
described that 
with T cell
T
Since the occurrence of CMV infection is more frequent in 
BMT recipients with a clonal expansion of CD8+ T cells 
(Table 1), one may speculate that some of the predominant 
clones represent CTL directed against MHC-class I-restric- 
tecl CMV antigens. Freshly isolated CD8+ T cells of recipi­
ent UPN 247 and UPN 265 after the onset of CMV infec­
tion, both consisting of a high percentages of clonal T cells, 
lysed CMV-infected fibroblasts of the HLA-identical donor 
(DV and BT, respectively; Figure 3). In contrast, CMV- 
infected fibroblasts of HLA-mismatched donors (VG and 
HB, respectively) were not killed. Moreover, uninfected 
fibroblasts of both HLA-matched and -mismatched donors 
could not be lysed by these CTL (Figure 3).
CD8+ T cells isolated from two BMT recipients, with a 
clonal expansion coincidental with CMV infection, 
mediated HLA-restricted CMV-specific cytotoxicity with­
out previous in vitro stimulation with CMV antigens. These Discussion 
results suggest that some of the clonally expanded CD8+
expansion and CMV infection after BMT.2 Therefore, we 
investigated whether expression of CD57 influence TCR 
clonality and CMV-specific cytotoxicity of CD81 T cells. 
CD8+CD57+ and CD8+CD57 T cell subsets showed the 
same predominant bands (Figure 4). SSCP analysis carried
out in a gel without glycerol, to enhance reliability of the 
occurrence of the same TCR in both 
identical results (data not shown).
We investigated whether CDS ' T cells defined by CD57
er in CMV-specific * « T
cells of recipient UPN 265 with significant CMV-specific 
cytotoxicity were sorted based on CD57 expression. CD8'
CD57+ or CD57 HLA-identical
CMV-infected fibroblasts, whereas uninfected and HLA- 
mismatched cells were not killed (Figure 5).
These results show that clonal CD8+ T cells can consist 
of both CD57+ and CD57~ cells. Moreover, CTL function
regarding CMV-specific cytotoxicity is not 
CD57 expression.
by
In the present study we show that clonal 
exists within CD8+ T cells of BMT recipients
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Figure 2 Follow-up of the representative recipient UFN 257 after BMT. 
(a) Repopulation of CD8‘ T cells in peripheral blood. Onset of CMV 
infection is 2 months after BMT. (b) PCR-SSCP analysis of TCR-y gene 
rearrangement of CD8f T cells.
expanded number of this T cell population. These C D 81 T
cells o fappear to be donor-derived.
CD8+ T cells, present in approximately half of the recipi­
ents, could be the result of complex mechanisms. Expan­
sion may be due to a better developing T cell system after 
BMT depending on the quality of the graft. CDS1 T cell 
expansion upon antigen stimulation by GVHD and virus 
infections might also be involved.
Clonal expansions within the CD8+ T cell population 
have been observed in BMT recipients,3“6 patients with 
autoimmune diseases,20,21 patients with chronic B cell lym­
phocytic leukemia (B-CLL),22 but also in normal adults.23,24 
Farace et al22 found a unique clonally e
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Figure 3 CMV-specific cytotoxicity of freshly isolated CDS' T cells of 
two BMT recipients 3 months after BMT. (a) CD81 T cells from recipient 
UPN 247 were tested against uninfected and CMV-infected fibroblasts 
from the HLA-identical donor DV (DV F, ™o , and DV F-CMV, 
respectively), uninfected and CMV-inlected fibroblasts from the I1I.A 
mismatched donor VG (VG F, - and VC» F-CMV, 
and EBV-LCL
I
respectively),
from the HLA-identical donor DV (DV-EBV, -A-).
(b) CDS' T cells from recipient UPN 265 were tested 
and CMV-infected fibroblasts from the HLA-identical donor BT (BT F,
o—, and BT F-CMV, , respectively), uninfected and CMV-infected
fibroblasts from the HLA-mismatched donor HB (HB F, - a - ,  and HB F-
CMV, »•M» , respectively), and EBV-LCL from the HLA-identical donor
BT (BT-EBV, -A -).
IS . In í et al2* showed that 
exposure to antigen induces such a clonal response. After
CD8'V/319+ T cell clone in a patient with a B-CLL that a booster with .ititis B vaccine a pre
dominant CD8+V/34+ T cell
After BMT the compositionThese observations support the hypothesis that clonally 
expanded CD8+ T cells represent antigen-specific effector correlated with GVHD and
T cell repertoire is 
status.6 Dietrich et
cells directed against antigens to which the immune system 3,4 have identified several recurrent TCR transcripts in
TCR clonality of CNIV-specific CTL after BMT
H Dolstra et al
UPN 247 UPN 257
r r
CD8+
CD57+
C D 8 +
CD57-
CD8+
CD57+
CD8+
CD57-
: • • v •'••• i'i'.s i':'■ •-iÿ .'VV;? V.: --Y, ' ': ':í1 •
* : . • 
*: ' * '
. 'y'-WWrP^  : f llivip
r .. ; .■ :.A ’■ • ■ '• •• • : ; : v
Figure 4 PCR-SSCP analysis of TCR-y gene rearrangement of sorted 
CD8'CD57+ and CD8+CD57- T cells.
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Figure 5 CMV-specific cytotoxicity of isolated CDS', CD8+CD57h and 
CD8+CD57" T cells of recipient UPN 265. These subsets were tested 
against uninfected and CMV-infected fibroblasts from the HLA-identical 
donor BT (BT F and BT F-CMV, respectively), uninfected and CMV- 
infected fibroblasts from the HLA-mismatched donor HB (HB F and HB 
F-CMV, respectively) and EBV-LCL from the HLA-identical donor BT 
(BT-EBV). The effector:target cell ratio was 10:1.
This suggests the presence of an adequate CMV-specific
CTL response.
Expansion of donor-derived CD8H T c e l l s  after BMT was 
accompanied by expression of the l in e a g e -n o n r e s tr ic te d  
glycoprotein CD57.2 Whether CD57 expression dividevS 
CD8+ T c e l l s  in d is t in c t  subsets w ith  unique functional
properties or reflect a differentiation or activation stage of 
these cells is not elucidated. In this study we show that 
CD8+CD57+ and CD8+CD57~ T cells have the same domi­
nant TCR-y gene rearrangement. Our results confirm and 
extend the observation of Morley et al24 who showed that 
the same T cell clone is present in both CD8+CD57+ and 
CD8+CD57~ T cells, but differ from a study of Gorochov 
et al.5 They reported that in allogeneic BMT recipients 
CD8+CD57+ T cells, but not the CD57~ cells, exhibited an 
oligoclonal pattern of TCR-y gene rearrangement. In con­
trast to our data, they compared CD8+CD57+ T cells with 
all CD57~ cells consisting of both CD8+ and CD4+ T cells. 
Depletion of CD4+ T cells results in less TCR variety in 
both subsets and therefore comparison of TCR clonality 
analysis between CD8'hCD57+ and CD8+CD57~ T cells is 
more conclusive. In addition, we show that within the CD8+ 
T cells both CD57+ and CD57“ T cells exert HLA-restric- 
ted CMV-specific cytotoxicity. This indicates that 
CD8+CD57+ T cells besides their reported inhibitory 
effects'0,11 and non-MHC-restricted cytotoxicity,7-9 also 
exert MHC-restricted cytotoxicity. From these results we 
conclude that TCR clonality and CMV-specilic cytotoxicity 
is independent of CD57 expression.
In a previous study we described that the expansion of 
CD8+ T cells after BMT was associated with both a lower 
incidence of leukemic relapse and occurrence of CMV 
infection.2 The data presented in this manuscript confirmed 
that CMV-specific CTL response indeed exist in some 
BMT recipients. This suggests that a CMV-specific CTL 
response may prevent leukemic relapse. One hypothesis is 
that donor-derived CMV-specific CTL cross-react with 
antigens presented on leukemic cells. Viral infections 
appear to stimulate the generation of alloantigen-specific 
CTL coincidental with the generation of virus-specific 
CTL.26 Burrows et al27 isolated CTL clones with specificity 
for an HLA-B8 restricted EBV epitope and cross-reacting 
with the alloantigen HLA-B44.02. Cao et al28 found CTL 
cross-reactivity between a H-2Kd restricted influenza epi-
tope and an immunoglobulin Vh Furthermore,
increased production of cytokines during a CMV-antigen 
stimulated immune response might induce proliferation of 
skin and blood at the time of acute GVHD suggesting that anti-leukemic CTL and enhance the susceptibility of leu- 
minor histocompatibility antigens induce clonal expansions. kemic cells to anti-leukemic CTL activity. In vitro TNF-a 
Our observation that occurrence of CMV infection is more 
frequent in BMT recipients with clonally expanded CD8+
T cells suggests that CMV antigens might also be a stimu-
can enhance susceptibility of leukemic cells to specific CTL 
activity (unpublished observation).
In conclusion, we demonstrate that CMV antigens stimu-
latory signal.2 Additionally, this study shows that CD8+ T late clonal proliferation of CD8+ CMV-specific CTL. The
majority of these cells express CD57.cells from BMT recipients with an expansion of these cells 
exert HLA-restricted CMV-specific cytotoxicity. CMV- 
specific CTL which are stimulated during CMV infection 
after BMT play an important role in the immunological 
control of CMV and provide protection against the develop­
ment of CMV disease.25 None of the BMT recipients in
this study with a CMV infection coincidental with clonally Locht for technical assistance and Marij Gielen for preparation of 
expanded CD8+ T cells developed clinical CMV disease.2 CMV stock. This work was supported in part by grants from the
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